Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4046/trd.2020.0063 http://scihub22266oqcxt.onion/10.4046/trd.2020.0063 32883062!7801810!32883062     free     free     free       Tuberc+Respir+Dis+(Seoul) 2021 ; 84 (1): 13-21 Nephropedia Template TP {{tp|p=32883062|t=2021. COVID-19 Death and BCG Vaccination Programs Worldwide |pdf=|usr=}}{{32883062}} gab.com Text COVID-19 Death and BCG Vaccination Programs Worldwide JO: Tuberc Respir Dis (Seoul) http://www.kidney.de/pget.php?&tw=1&pmid=32883062 #FOAvip Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guerin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases. Twit Text FOAVip COVID-19 Death and BCG Vaccination Programs Worldwide ????Tuberc Respir Dis (Seoul) http://www.kidney.de/pget.php?&tw=1&pmid=32883062 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32883062 #FOAvip English Wikipedia <ref>{{Cite pmid|32883062}}</ref> COVID-19 Death and BCG Vaccination Programs Worldwide #MMPMID32883062 Jirjees FJ; Dallal Bashi YH; Al-Obaidi HJ Tuberc Respir Dis (Seoul) 2021[Jan]; 84 (1): 13-21 PMID32883062show ga Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guerin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases. ?COVID-19 Death and BCG Vaccination Programs Worldwide (epmc).pdf DeepDyve Pubget Overpricing